Global Nucleic Acid Therapeutics Market by Type (DNA-Based Therapeutics, RNA-Based Therapeutics), by Therapeutic Area (Cancer, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), by Route of Administration (Intravenous, Subcutaneous, Oral), by End-Use Industry (Healthcare and Medical, Research and Development, Pharmaceutical Companies) and By Region: Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Nucleic Acid Therapeutics Market was valued at USD 10.6 Billion in 2024-e and will surpass USD 27.3 Billion by 2030; growing at a CAGR of 17.0% during 2025 - 2030.

 The Nucleic Acid Therapeutics market is a rapidly growing segment within the broader biopharmaceutical industry, driven by innovations in gene therapy, RNA-based treatments, and DNA therapeutics. Nucleic acid-based therapies offer significant potential for treating a variety of diseases, including genetic disorders, cancer, and infectious diseases, by targeting the underlying molecular causes of these conditions. The increasing prevalence of chronic diseases, advancements in gene-editing technologies, and growing investment in personalized medicine have contributed to the expansion of this market. With the successful approval of mRNA vaccines and other nucleic acid-based drugs, the industry is poised for continued growth, offering new opportunities for pharmaceutical companies and healthcare providers.

RNA-Based Therapeutics Segment Is Fastest Growing Owing To Advancements in mRNA Technology

RNA-based therapeutics, particularly mRNA-based treatments, represent the fastest growing segment in the Nucleic Acid Therapeutics market. The success of mRNA vaccines, especially in the fight against COVID-19, has significantly accelerated interest and investment in RNA-based therapies. These therapies work by using messenger RNA to instruct cells to produce proteins that can treat or prevent disease, offering a novel approach compared to traditional drug therapies. The ability to quickly develop and manufacture mRNA therapies for a wide range of infectious diseases, genetic disorders, and even cancer is a key factor in their rapid adoption.

RNA-based therapeutics are not only revolutionizing vaccine development but also showing promise in the treatment of genetic disorders such as cystic fibrosis, Duchenne muscular dystrophy, and hemophilia. As research progresses, RNA-based therapies are expanding into other therapeutic areas, including cancer and neurological disorders. With ongoing advancements in RNA delivery technologies and growing regulatory support, the RNA-based therapeutics market is expected to continue its strong growth trajectory, offering significant opportunities for innovation in the biopharmaceutical sector.

Cancer Therapeutic Area Is Largest Owing To High Unmet Medical Need and Market Potential

Cancer is the largest therapeutic area within the Nucleic Acid Therapeutics market, driven by the high unmet medical need for effective treatments. Cancer therapies based on DNA and RNA technology are gaining traction due to their ability to target the genetic and molecular mechanisms behind tumor growth. Gene therapies and RNA-based treatments offer the potential to treat cancer more precisely by focusing on the genetic mutations that drive cancer progression. These therapies can either correct defective genes or modulate the expression of specific proteins involved in cancer, allowing for more effective treatment with fewer side effects.

The rapid advancements in immuno-oncology and gene-editing technologies, such as CRISPR, are significantly enhancing the potential of nucleic acid therapeutics in cancer treatment. With a growing focus on personalized medicine and targeted therapies, nucleic acid-based treatments are positioned to transform cancer care. The high market potential, combined with increasing research into innovative cancer treatments, makes cancer the largest and most lucrative therapeutic area in this market.

Healthcare and Medical End-Use Industry Is Largest Owing To Increasing Demand for Targeted Therapies

The healthcare and medical end-use industry holds the largest share in the Nucleic Acid Therapeutics market. The growing demand for personalized and targeted therapies is driving the adoption of nucleic acid-based treatments in clinical settings. Healthcare providers are increasingly relying on gene therapies, RNA-based therapeutics, and DNA-based treatments to address a wide range of chronic conditions, from genetic disorders to cancer and infectious diseases. The ability of these therapies to target specific molecular causes of disease represents a significant advancement over traditional drug treatments, making them highly sought after in the medical field.

In addition, the rising prevalence of genetic diseases, cancer, and other chronic conditions is driving the demand for innovative treatments. The rapid development and approval of nucleic acid-based drugs, including gene therapies for rare genetic disorders, are contributing to the growth of this segment. As the healthcare industry increasingly shifts toward precision medicine, the demand for nucleic acid therapeutics in hospitals, clinics, and other medical facilities is expected to grow, further expanding the market.

Intravenous Route of Administration Is Largest Owing To Its Efficiency in Delivering Therapeutics

The intravenous (IV) route of administration is the largest segment in the Nucleic Acid Therapeutics market. IV administration is preferred for many nucleic acid-based therapies due to its ability to deliver therapeutic agents directly into the bloodstream, ensuring rapid distribution and effective delivery to the target tissues. This is particularly important for the treatment of systemic diseases like cancer and genetic disorders, where precise and widespread distribution of the therapeutic agent is critical for efficacy.

The ability to administer nucleic acid therapeutics intravenously also enhances patient compliance, as many of these therapies require careful monitoring during administration. Additionally, advances in intravenous drug delivery systems are improving the safety and effectiveness of these treatments, further driving their popularity in clinical settings. As new nucleic acid-based drugs continue to be developed, the intravenous route of administration will remain the preferred choice for many therapeutic applications.

North America Region Is Largest Owing To High Healthcare Spending and Research Investment

North America dominates the Nucleic Acid Therapeutics market, driven by the region's advanced healthcare infrastructure, high healthcare spending, and significant investment in biotechnology research and development. The United States, in particular, leads the market due to its well-established pharmaceutical industry, strong regulatory framework, and high demand for advanced therapeutics. North America has been at the forefront of developing and commercializing nucleic acid-based therapies, including mRNA vaccines and gene therapies, which has further solidified the region’s dominant position.

The presence of leading pharmaceutical companies, coupled with the growing focus on personalized medicine, has positioned North America as the largest market for nucleic acid therapeutics. Additionally, government support and initiatives to foster innovation in gene and RNA therapies are driving market growth. As more nucleic acid-based treatments receive regulatory approval and enter the market, North America is expected to continue leading the global market.

Competitive Landscape and Key Players

The Nucleic Acid Therapeutics market is highly competitive, with numerous biotech companies and pharmaceutical giants vying for market share. Leading players in the market include companies such as Moderna, Pfizer, Novartis, Sangamo Therapeutics, and BioNTech. These companies are at the forefront of developing RNA-based therapies, DNA therapeutics, and gene editing technologies. Moderna and BioNTech, for example, gained global recognition for their mRNA COVID-19 vaccines, and they are now exploring the use of mRNA technology for other therapeutic areas, such as cancer and genetic disorders.

The competitive landscape is marked by ongoing innovation, strategic partnerships, and mergers and acquisitions, as companies seek to expand their product portfolios and enhance their capabilities. With the growing interest in gene therapies and RNA-based treatments, competition in the Nucleic Acid Therapeutics market is expected to intensify. Companies are focused on improving the delivery systems for nucleic acids, optimizing therapeutic efficacy, and addressing challenges such as cost and patient accessibility to maintain a competitive edge.

Recent Developments:

• Moderna, Inc. announced positive clinical trial results for its mRNA-based therapeutic for treating cardiovascular diseases, showing promising results in reducing plaque build-up.
• BioNTech SE received approval from regulatory agencies for its RNA-based cancer treatment, marking a breakthrough in personalized cancer immunotherapy.
• Sarepta Therapeutics, Inc. launched a new RNA-based therapy for Duchenne muscular dystrophy, improving patient outcomes in clinical trials.
• Gilead Sciences, Inc. expanded its nucleic acid therapeutics pipeline by acquiring a company focused on RNA interference technologies for treating rare genetic disorders.
• Alnylam Pharmaceuticals, Inc. completed successful Phase III trials for its RNA-based treatment for hereditary transthyretin amyloidosis, paving the way for future commercialization.

List of Leading Companies:

• Moderna, Inc.
• Alnylam Pharmaceuticals, Inc.
• Gilead Sciences, Inc.
• BioNTech SE
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Vertex Pharmaceuticals Incorporated
• Editas Medicine, Inc.
• CRISPR Therapeutics AG
• Sangamo Therapeutics, Inc.
• Regeneron Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Co.

Report Scope: